Navigation Links
Inspiro Medical Ltd. Completes a Successful First Clinical Trial in Asthmatic Children
Date:6/6/2013

TEL AVIV, Israel, June 6, 2013 /PRNewswire/ --

Inspiro Medical, a portfolio company of The Trendlines Group, recently completed a successful clinical trial for InspiromaticTM, its innovative, breath-synchronized, active dry powder inhaler.

The study, completed in May 2013 at Schneider Medical Center aimed to objectively assess, in a randomized, crossover, double blind study, the efficacy and safety profiles of formoterol (bronchodilator) treatment via the Inspiromatic in asthmatic children, compared to its delivery via a competitive inhaler already on the market.

30 children with asthma, aged 8-18, were randomly allocated to treatment with formoterol via the Inspiromatic inhaler or a competitive device.

The study met both primary and secondary endpoints. The results demonstrated superior results for of the Inspiromatic in pulmonary delivery of the active drug. Lung function test (FEV1) demonstrated a statistically significant improvement following formoterol delivery via the Inspiromatic. Moreover, the Inspiromatic was highly rated by patients. Successful delivery of the API was achieved even with patients with poor inhalation technique and even in low-flow inhalation rate.  

"I'm very happy with the study results showing that the Inspiromatic achieved safety and efficacy," said Nimrod Kaufmann , CEO of Inspiro Medical. "This successful study will enable us to move to the next step in the company development and partner with pharmaceutical companies to develop drug-device combinations and also bring better therapy to patients with poor inhalation technique."  

Despite the numerous aerosol delivery devices currently on the market, Inspiro Medical believes that their device can significantly improve effectiveness in deposing the necessary medication. Inspiromatic takes into account drug particle/droplet size; design of the delivery device; and the patient's ability to use and understand the device.

Following this successful trial, Inspiro Medical will continue partnering with global pharmaceutical companies to jointly develop combination products.

Inspiro Medical will be opening investment round A in Q3/2013 to further develop its device and support partnering activities.

Nimrod Kaufmann will present Inspiro's proven technology at BioMed 2013 in Tel Aviv on June 10.

Company contact details:

Nimrod Kaufmann , CEO
Tel: +972-72-260-7051
E-mail: info@inspiromedical.com
Website: http://www.inspiromedical.com

Media relations:

Efrat Kaduri
Ofir Shpigel Media and Public Relations
+972-4-9535030


'/>"/>
SOURCE Inspiro Medical Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Standardized Regulations Crucial for Growth in Global Dimensional Metrology Market for Medical Devices
2. Chicago Crime Commission calls on Gov. Quinn to veto medical marijuana bill
3. More Than 100 Winning Medicare Bidders In Maryland Dont Have Proper Licenses To Provide Medical Equipment To Patients
4. Astute Medical, Inc. patrocinerà il simposio informativo presso il meeting sulla nefrologia in terapia intensiva
5. Astute Medical, Inc., veranstaltet Symposium aus anlaß des Critical Care Nephrology Kongress
6. Astute Medical, Inc. va accueillir un symposium éducatif lors dune réunion dédiée à la réanimation néphrologique
7. UBM Canon Celebrates the 30th Anniversary of MD&M East, the East Coasts Largest Medical OEM Event, and the 15th Anniversary of the Medical Design Excellence Awards, the MedTech Industrys Premier Awards Program
8. MAQUET Medical Systems USA Launches LED Concealed Lighting System For Labor, Delivery And Recovery Room
9. Cheetah Medical Announces New Management Team
10. seca Launches the seca mBCA 514 - medical Body Composition Analyzer
11. Kettering Medical Center Acquires Elektas Versa HD Radiotherapy System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Juan Monteverde , founder ... , a boutique securities firm headquartered at the Empire ... , announces that a class action lawsuit has been ...  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the ... July 23, 2015 and December 30, 2016, inclusive (the ...
(Date:2/24/2017)... YORK , Feb. 23, 2017 Report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. ... Market data and analytics are derived from primary and secondary ...
(Date:2/24/2017)... le 24 février 2017 ITL Limited, ( ASX : ITD ... est ravie d,annoncer les excellents résultats semestriels clos le ... correspondante. Une présentation complète « Résultats et mise à jour ... ici . Faits marquants ... 2015 : 1,04 million $ ; en hausse de 104 %) ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... cognitive rehabilitation, according to a study released today at the 1st Pan American ... programs are proven to be effective in improving cognitive function in PD patients. ...
(Date:2/25/2017)... Viejo, CA (PRWEB) , ... February 25, 2017 , ... ... with ProSharpen Color tools from Pixel Film Studios. With ProSharpen Color users have total ... sliders to easily refine their color range. With color spectrum tools users can visually ...
(Date:2/24/2017)... TX (PRWEB) , ... February 24, 2017 , ... ... offering promotions on tooth replacement options at his office, Antoine Dental Center. Currently, ... implants for $18,499. Some restrictions may apply, but patients can learn more about ...
(Date:2/24/2017)... NJ (PRWEB) , ... February 24, 2017 , ... ... that provides business development, education, networking and recognition opportunities as well as advocacy ... Bell Works in Holmdel, NJ on February 23. The Council's Innovation Forecast ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. ... has officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio ...
Breaking Medicine News(10 mins):